Leflunomide is not recommended for patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections; significant hepatic impairment or evidence of infection with hepatitis B or C viruses.
If a patient taking leflunomide develops Stevens-Johnson syndrome, leflunomide therapy should be stopped, and a drug elimination procedure is recommended.
The risk of malignancy, particularly lymphoproliferative disorders, is increased with the use of some immunosuppression medications.
The possibility that adverse effects or drug interactions associated with the drug could continue to occur even though the patient is no longer receiving leflunomide should be considered.
Interstitial lung disease is a potentially fatal disorder, which may occur acutely at any time during therapy with leflunomide.
Leflunomide should be used with caution in patients with renal impairment.
Patients should be aware of how they react to drug before driving or operating machinery.